Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is an issue of global significance that has taken the lives of many across the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for its pathogenesis. The pulmonary manifestations of COVID-19 have been well described in the literature. Initially, it was thought to be limited to the respiratory system; however, we now recognize that COVID-19 also affects several other organs, including the nervous system. Two similar human coronaviruses (CoV) that cause severe acute respiratory syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS-CoV) are also known to cause disease in the nervous system. The neurological manifestations of SARS-CoV-2 infection are growing rapidly, as evidenced by several reports. There are several mechanisms responsible for such manifestations in the nervous system. For instance, post-infectious immune-mediated processes, direct virus infection of the central nervous system (CNS), and virus-induced hyperinflammatory and hypercoagulable states are commonly involved. Guillain-Barré syndrome (GBS) and its variants, dysfunction of taste and smell, and muscle injury are numerous examples of COVID-19 PNS (peripheral nervous system) disease. Likewise, hemorrhagic and ischemic stroke, encephalitis, meningitis, encephalopathy acute disseminated encephalomyelitis, endothelialitis, and venous sinus thrombosis are some instances of COVID-19 CNS disease. Due to multifactorial and complicated pathogenic mechanisms, COVID-19 poses a large-scale threat to the whole nervous system. A complete understanding of SARS-CoV-2 neurological impairments is still lacking, but our knowledge base is rapidly expanding. Therefore, we anticipate that this comprehensive review will provide valuable insights and facilitate the work of neuroscientists in unfolding different neurological dimensions of COVID-19 and other CoV associated abnormalities.

Introduction

Since December 2019, the health effects of a novel coronavirus (CoV) disease have been witnessed in a worldwide outbreak of severe pneumonia caused by a deadly infectious virus originating in Wuhan, China. From the first human CoV-positive cases detected in Wuhan (WHO 2020), coronavirus disease 2019 (COVID-19) has spread rapidly in humans around the globe. SARS-CoV-2, a strain of CoV, causes the clinical syndrome COVID-19, whose pulmonary manifestations have been well recorded. The increasing number of positive cases has reached more than 54.7 million, with 1,323,230 deaths reported as of November 15, 2020 (Worldometer 2020). A very interesting fact about this virus is that a higher lethality of infection has been recognized in those over the age of 65 and patients with comorbidities (Baud et al. 2020; Guan et al. 2020; Huang et al. 2020; Wang et al. 2020a, b, c, d).

There is increasing evidence of neurological complications detected in patients due to SARS-CoV-2, and this raises the question of whether SARS-CoV-2 is neurotropic and whether it contributes to post-infectious neurological complications. Two similar human CoVs, severe acute respiratory syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS-CoV), have also been reported to be associated with neurological disease in uncommon cases. A handful of case reports have described neurological complications in patients with COVID-19 (Huang et al. 2020; Netland et al. 2008; Zhang 2020; Kim et al. 2017). However, owing to a lack of understanding of the specific mechanisms, it remains unclear to what extent SARS-CoV-2 itself affects or damages the nervous system, and what neurological symptoms are attributable to secondary mechanisms. Viral neuroinvasion may be achieved by several routes, including entry via the olfactory nerve, transsynaptic transfer across infected neurons, leukocyte migration across the blood–brain barrier (BBB), or infection of the vascular endothelium. SARS-CoV-2 mainly affects the lower respiratory tract, and the most common and frequent neurological complaints in COVID-19 are anosmia, ageusia, and headache, along with others including fever, fatigue, myalgia, dry cough, and diarrhea (Gutiérrez-Ortiz et al. 2020). Additionally, coma, seizure, stroke, encephalopathy, and impaired consciousness have also been observed (Gutiérrez-Ortiz et al. 2020). The identification and understanding of the array of COVID-19-associated neurological diseases may lead to improved clinical outcomes and better treatment algorithms. This comprehensive review serves to recapitulate available data related to CoV in the nervous system, identify the potential tissue targets and entry routes of SARS-CoV-2 into the CNS, and address the array of clinical neurological manifestations and complications that have been recorded so far in COVID-19 and their potential pathomechanisms. Further neuropathological studies will be significant in order to understand the disease pathogenesis and the interconnection between SARS-CoV-2 and the CNS. Most importantly, longitudinal neurological and cognitive assessment of individuals after recovery from COVID-19 will be crucial for understanding the natural history of COVID-19 in the CNS and monitoring for any long-term neurological sequelae.

Neurological Complications of SARS-CoV-2 and Other Coronaviruses

Recent evidence suggests that the nervous system might also be involved in the COVID-19 pathophysiology. As revealed by a retrospective study of 200 patients in China, neurological symptoms were experienced by a subset of patients affected by COVID-19 (Mao et al. 2020). The neurological symptoms that were experienced include impaired consciousness, skeletal muscle symptoms, and acute cerebrovascular disease, all of which indicated the involvement of the peripheral nervous system (PNS) and central nervous system (CNS). Patients suffering from severe COVID-19 were more likely to exhibit these symptoms. Hyposmia and hypogeusia were other possible PNS symptoms that were observed. As patients were hospitalized at the time of publication, it was not possible to investigate the link between patient outcome and neurological symptoms. In another study conducted on the same group of patients, it was revealed that COVID-19 infection in 13 patients was followed by acute cerebrovascular diseases, including cerebral hemorrhage, ischemic stroke, and cerebral venous sinus thrombosis (Li et al. 2020a, b).These features were observed more commonly in older patients and patients with severe disease. A second study conducted in France reported similar neurological manifestations as were revealed in a Chinese study, where 58 patients with COVID-19 experienced acute respiratory distress syndrome and had to be admitted to a hospital (Helms et al. 2020). Neurological symptoms were observed in 85% of the patients at various points in time, with consequences ranging from the discontinuation of neuromuscular blockade to admission to the intensive care unit (ICU). Neurological features included corticospinal tract dysfunction, encephalopathy, delirium, and agitation. Bilateral frontotemporal hypoperfusion and leptomeningeal enhancement were also revealed in a small subset of patients on conducting perfusion brain imaging and magnetic resonance imaging (MRI). Evidence of small acute ischemic stroke was also present in two patients. While further studies are needed to characterize the associated neurological manifestations, the number of COVID-19 cases with a reported acute neurological disorder is increasing, ranging from acute myelitis and Guillain-Barré syndrome (GBS) to hemorrhagic necrotizing encephalopathy (Karimi et al. 2020; Zhao et al. 2020a, 2020b; Poyiadji 2020; Moriguchi 2020; Sedaghat and Karimi 2020; Toscano et al. 2020). Compared to past instances of coronavirus epidemics, significantly fewer neurological associations have been established, but several case reports of patients with severe acute respiratory syndrome coronavirus (SARS-CoV) have described patients developing rhabdomyolysis, myopathy, and seizures (Lau et al. 2004; Tsai et al. 2005; Hung et al. 2003; Chao et al. 2003; Xu et al. 2005). In a study that involved 206 SARS patients, acute cerebrovascular disease was reported in five cases (Umapathi 2004). However, it is debatable whether this indicates a direct comparison between SARS pathophysiology and COVID-19. Acknowledging that in some cases these are associated with different diagnoses, and noting that they are rare presentations, the presence of RNA in both autopsied brain tissue (Xu et al. 2005) and cerebrospinal fluid (CSF) (Lau et al. 2004; Tsai et al. 2005; Hung et al. 2003) suggests a neurotropic component of the SARS coronavirus. Furthermore, several case reports of patients during the MERS-CoV outbreak noted neurological disorders, including delirium, neuropathy, and acute cerebrovascular disease (Kim et al. 2017; Algahtani et al. 2016; Arabi et al. 2015). Seizures in six participants and confusion in 18 patients were reported during another study that involved 70 MERS patients (Saad et al. 2014), although caution is warranted in the interpretation of such findings. There is little evidence that indicates the presence of MERS coronavirus in CSF as compared to SARS. It seems to be the same case with COVID-19; where evidence of the presence of the virus in the CSF is restricted to a single report (Moriguchi 2020) whose findings have not been replicated by other studies (Helms et al. 2020; Karimi et al. 2020; Toscano et al. 2020). Over a million confirmed cases of COVID-19 have been reported worldwide, and while definitive evidence is sparse, emerging publications and preprints justify careful consideration of the neurological associations with COVID-19 infection (Fig.1).

Fig. 1.

Schematic representation showing the possible mechanisms underlying neurological consequences of COVID-19. CBF, cerebral blood flow; CPP, cerebral perfusion pressure

Direct Neuroinvasive Effects of SARS-CoV-2 and Other Coronaviruses on the Nervous System 

An important line of research pertains to the question of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is neuroinvasive. Much published evidence is available on this issue. Similar to SARS-CoV, the molecular mechanisms underlying cell invasion by SARS-CoV-2 are related to the capacity of the virus to bind to angiotensin-converting enzyme 2 (ACE2) receptors. The CNS is a potential target for SARS-CoV-2, because the ACE2 receptors are highly expressed in the neurons and glial cells in the CNS and epithelial cells of the digestive and respiratory systems (Xu et al. 2020a; Zhang et al. 2020; Lukassen et al. 2020; Wong et al. 2020; Baig et al. 2020). Emerging data suggest that ACE2 receptors are expressed in multiple regions of the human and mouse brain, including the posterior cingulate cortex, motor cortex, substantia nigra, ventricles, olfactory bulb, middle temporal gyrus, nucleus of tractus solitarius, ventrolateral medulla, and dorsal motor nucleus of the vagus nerve, and on several key cell types that make up the CNS including neurons, astrocytes, microglia, and oligodendrocytes (Fig. 2) (Chen et al. 2020a; Xia and Lazartigues 2008; Doobay et al. 2007). Moreover, neuronal death in mice has been exhibited with SARS-CoV as it invades the CNS through the cribriform plate of the ethmoid bone and, subsequently, the olfactory neuroepithelium (Netland et al. 2008). The entry of SARS-CoV-2 into the CNS is also possible through the hematogenous route. With the presence of the virus in the general circulation and the slow blood flow, the ACE2 receptors expressed in the capillary endothelium may interact with SARS-CoV-2 (Zhang et al. 2020). Endothelial damage and cerebral bleeding observed in patients suffering from COVID-19 may also be due to this mechanism. Moreover, preliminary evidence suggests that there might be prognostic implications in the acute phase for the neuroinvasive potential of SARS-CoV-2. It has been hypothesized that any death that is entirely due to severe respiratory involvement is mediated by central hypoventilation syndrome secondary to CNS invasion (Li et al. 2020a, b). When a review of the Wuhan reports involving 214 COVID-19 patients was conducted, neurological symptoms were observed in more than 36% of individuals. Patients who exhibited neurological manifestations suffered from severe COVID-19. In addition, the neurological symptoms that were reported most frequently were acute stroke (both ischemic and hemorrhagic), skeletal muscle damage, and impaired consciousness (Mao et al. 2020). Evidence of CNS invasion has subsequently been displayed in patients affected by SARS-CoV-2. Researchers at the Beijing Ditan Hospital used genome sequencing to identify SARS-CoV-2 in the CSF of a patient affected with clinical encephalitis and COVID-19, but it has still not been determined whether SARS-CoV-2 remains in the CNS over the medium or long term (Mao et al. 2020). However, viral latency in the CNS has been described for other viruses as well, including some coronaviruses. For example, in the CNS, human coronavirus OC43 (HCoV-OC43) was detected after more an year post-inoculation in a murine model of coronavirus encephalitis (Xiang et al. 2019; Jacomy et al. 2006). How the virus can persist in the CNS is a question that has been the subject of debate. There have been suggestions that inflammatory and cytolytic strategies that have shown potential in the control of viral infection cannot be used in the brain by the immune system, as they can have potentially devastating consequences. Thus, another type of immune response is initiated in the CNS, which favors viral latency in the CNS as well as reactivation in situations that are entirely favorable (Miller et al. 2016). The possibility that SARS-COV-2 might remain suppressed in the CNS cannot be ruled out entirely. If it does, delayed onset of neurological symptoms might be observed as a result of viral reactivation in the medium or long term. This might eventually result in the reactivation of a series of processes that are neuroinflammatory in nature and are linked to neurodegenerative diseases.

Fig. 2.

a Human cells that express ACE2 receptors in the CNS. b Brain areas that express ACE2 receptors. c Binding of SARS-CoV-2 to a neuron (ACE2 receptors on a medullary neuron binding to the SPIKE protein on SARS-CoV-2)

Indirect Neuroinvasie Effects of Coronaviruses on the Nervous System

There may be an indirect effect of SARS-CoV-2 on the CNS, more specifically on the progression of disorders that are neurodegenerative in nature. In the past few years there have been descriptions of a strong correlation between neuroinflammation, microbiota, and CNS diseases. SARS-CoV-2 is also known to trigger inflammation and intestinal dysbiosis, infecting the mucosa cells, which potentially results in short-term and long-term alterations in the gut microbiota. This usually leads to the development of neurodegenerative diseases and neurodegeneration (Lin et al. 2018).

Possible Mechanisms of Coronavirus Infections in Neuronal Impairment

Direct Infection Injury

There have been suggestions that direct invasion of the nervous system by viruses is possible, which often lead to nerve damage. This is based on the detection of proteins and genetic materials of different viruses in tissue samples of the nervous system, including the CSF/brain (Koyuncu et al. 2013; Leber et al. 2016).

a) Blood Circulation Cascades

Japanese encephalitis virus (JEV) is a classic virus that uses the circulation of the blood to enter the CNS. It then undergoes multiplication in the vascular cells of the skin area, impacted by the mosquito bite. Subsequently, for reproduction in the mononuclear macrophages throughout the body, the virus is released into the blood. Through the cytokines produced, the secondary release into the bloodstream increases the BBB permeability. This promotes the virus’s entry into the brain, thereby leading to viral encephalitis (Unni et al. 2011). Additional studies are expected to determine whether the CoV, particularly SARS-CoV-2, can use the blood circulation pathway to invade the nervous system, as present evidence is extremely rare (Koyuncu et al. 2013; Desforges et al. 2019).

b) Neuronal Cascades

The neuronal pathway is an important vehicle facilitating the entry of neurotropic viruses into the CNS. Migration of the viruses is possible through infection of motor or sensory nerve endings, achieving retrograde or anterograde neuronal transport through the motor proteins, dynein, and kinesins (Swanson and McGavern 2015). Olfactory neuron transport is an example of a neuronal pathway. The olfactory bulb in the forebrain and the nasal cavity and olfactory nerves have a distinct anatomical structure, which makes it an efficient channel between the CNS and nasal epithelium (Koyuncu et al. 2013). Consequently, during the initial stages of infection or nasal vaccination, CoV can use the olfactory tract to enter the brain (Desforges et al. 2019; Mori 2015). For instance, once CoV infects the nasal cells, it can use the olfactory bulb and olfactory nerves to reach the CSF and the entire brain within one week, leading to demyelinating reaction and inflammation. However, the invasion of CoV into the CNS was restricted after removal of the olfactory bulb in mice (Bohmwald et al. 2018). SARS virus particles as well as genome sequences in brain neurons were also detected by Gu et al. (Gu et al. 2005). This observation suggests that CNS can be invaded by CoV through the periphery via neural pathways.

Hypoxia Brain Injury

Formation of transparent membranes, edema, and diffusion of alveolar and interstitial inflammatory exudation is caused by a virus when it proliferates in the lung tissue cells. This results in increased anaerobic metabolism in the mitochondria of brain cells and causes hypoxia through alveolar gas exchange disorders in the CNS (Abdennour et al. 2012). Various disorders can be caused by the accumulation of the acid, including obstruction of cerebral blood flow, cerebral vasodilation, interstitial edema, swelling of brain cells, and even headache due to ischemia and congestion (Abdennour et al. 2012). Cerebral circulation disorder and cerebral edema can also quickly worsen if the hypoxia continues unabated. Brain function gradually deteriorates with intracranial hypertension and may lead to bulbar conjunctival edema, drowsiness, and coma, (Abdennour et al. 2012). Moreover, acute cerebrovascular diseases such as acute ischemic stroke may be induced by hypoxia in patients who are at a higher risk of developing cerebrovascular disease. Hypoxia injury may lead to further damage to the nervous system, because severe hypoxia is commonly found in patients affected by COVID-19 (Guo et al. 2020).

Immune-Based Injury

The immune system might mediate the viral infection that causes damage to the nervous system (Klein et al. 2017). The development of a systemic inflammatory response syndrome (SIRS) is closely related to the pathology of severe viral infections. In cases of pneumonia triggered by CoV infection, abnormal initiation of SIRS is possible. The risk of injury to the nervous system and immune damage can be prevented by timely anti-inflammatory intervention (Mehta et al. 2020; Fu et al. 2020). In addition, a significantly higher number of casualties have been caused by COVID-19 and SARS predominantly due to multi-organ failure (MOF), which is a result of virus-induced SIRS or SIRS-like immune disorders (Yin et al. 2004; Chen et al. 2020b). The ability of CoV infections to persist and infect microglia, macrophages, and astrocytes in the CNS is crucial. A pro-inflammatory state can also be induced by glial cell activation via a neurotropic virus (Li et al. 2004). There is a positive correlation between interleukin (IL-6), which is an important member of the cytokine storm, and the symptoms of COVID-19 (Wan et al. 2020). Experiments have confirmed that a large number of inflammatory factors, including IL-12, IL-15, IL-6, and tumor necrosis factor alpha (TNF-α), are secreted by primary glial cells once they have been infected with CoV (Bohmwald et al. 2018). Chronic inflammation and brain damage are also caused by the activation of immune cells in the brain.

Angiotensin-Converting Enzyme 2 (ACE2)

As a cardio-cerebral vascular protection factor, ACE2 exists in various organs, including the skeletal muscles and the nervous system. It plays an essential role in anti-atherosclerosis mechanisms and regulation of blood pressure (Miller and Arnold 2019). Moreover, ACE2 is an extremely important target for various influenza viruses and CoV (Turner et al. 2004; Wrapp et al. 2020; Yang et al. 2014). The increased risk of cerebral hemorrhage and abnormally elevated blood pressure may be caused by these viruses by binding to the ACE2 receptors. Moreover, the virus has the potential to damage the BBB and enter the CNS by attacking the vascular system, as the ACE2 expressed in the capillary endothelium can interact with the SARS-CoV-2 spike protein (Baig et al. 2020).

Other Associated Factors

Neurological damage can be caused by CoV infections, as the biological properties of the CNS may facilitate their exacerbation. The invasion of the virus is inhibited by the lack of permeability of the blood vessels due to the dense parenchymal structure of the CNS. However, if any virus has access to the CNS, it is not easily removed (Reinhold and Rittner 2017). The eradication of viruses in nerve cells depends mainly on the role of cytotoxic T cells because of the lack of major histocompatibility complex (MHC) antigens in nerve cells, although a relatively protective effect is provided by apoptosis of mature neurons after virus infection (Wuthrich et al. 2015). Moreover, the continued existence of the virus also contributes to the homeostasis characteristics of the cells in the CNS (Reinhold and Rittner 2017). The possible mechanisms of nervous system injury caused by CoV are depicted in (Fig.3).

Fig. 3.

Schematic representation showing pathomechanisms of nervous system injury caused by coronaviruses (CoV). ACE2, angiotensin-converting enzyme 2; BBB, blood–brain barrier; IL, interleukin; MHC, major histocompatibility complexes; SIRS, systemic inflammatory response syndrome

Pathobiology of SARS-COV-2 Neuroinvasion

At present, it is unclear how the human CNS is invaded by SARS-CoV-2. Few researchers have postulated plausible mechanisms of neuroinvasion of SARS-CoV-2 through transsynaptic or BBB spread (Fig. 4) (Dube et al. 2018).

Fig. 4.

Transsynaptic viral spread: (a) Spread via the transcribrial route: Coronavirus (CoV) has been shown to spread via the transcribrial route from the olfactory epithelium along the olfactory nerve to the olfactory bulb within the CNS. (b) Spread via transsynaptic transfer: CoV has been shown to spread retrograde via transsynaptic transfer using an endocytosis or exocytosis mechanism and a fast axonal transport (FAT) mechanism of vesicle transport to move virus along microtubules back to neuronal cell bodies. Mechanisms of spread across the BBB: (c) Leukocyte infection: Infected leukocytes can cross the BBB to infect the CNS through the Trojan horse mechanism. (d) Endothelial infection: Infected vascular endothelial cells have been shown to spread SARS-CoV-2 to glial cells in the CNS

Transsynaptic Viral Spread

In the literature, the path of transsynaptic spread has been described for HCoV-OC43, hemagglutinating encephalomyelitis virus-67 (HEV67), and avian bronchitis virus (Dube et al. 2018). For inter- and intra-neuronal spread of neurotrophic virus, axonal microtubules facilitate molecular movement across axons either in antegrade or retrograde fashion (Desforges et al. 2019; Berth et al. 2009). A few reports have noted an isolated loss of smell (anosmia) and loss of taste (ageusia) with or without the invasion of respiratory system (Giacomelli et al. 2020). Researchers noted that the direct entry of SARS-CoV-2 along the olfactory nerve is a potential route for the virus to gain entry into the CNS (Matsuda et al. 2004). Few reports have proved a transcribrial route of spread in preclinical studies for SARS-CoV-1, MERS-CoV, and HCoV-OCR43 models through the intranasal route (McCray et al. 2007). Brann et al. and Fodulian et al. suggested the presence of ACE-2 receptors in sustentacular stem cells in the olfactory epithelium (Fodoulian et al. 2020; Brann et al. 2020). However, there is a scarcity of reports of olfactory neuropathy that is SARS-related (Hwang 2006). The most important COVID-19 infection features, which are being increasingly recognized as hyposmia and anosmia, are now the more common presenting symptoms (Mao et al. 2020; Lechien et al. 2020; Menni et al. 2020; Wolfel et al. 2020; Giacomelli et al. 2020; Bagheri et al. 2020). According to animal studies, it has been suggested that SARS-CoV can reach the brain and promote neurodegeneration through the olfactory route (Netland et al. 2008). These clinical reports help researchers trace the path of olfactory epithelial damage underlying clinical anosmia (Brann et al. 2020; Fodoulian et al. 2020).

Blood–Brain Barrier (BBB) Spread

Hematogenous dissemination is one of the suggested mechanisms, wherein the endothelial cells or leukocytes are infected by the virus that traverses from the bloodstream into the CNS (Desforges et al. 2019). The neural spread of SARS-CoV-2 via the BBB is through the spread of infection across vascular endothelial cells due to the presence of ACE2 receptors in the endothelial cells (Paniz-Mondolfi et al. 2020). Once a neurotrophic virus gains entry along vascular endothelial cells, the virus is integrated with cells containing ACE2 receptors (neurons, glia and vascular channels) and is able to exert its effects (Baig et al. 2020). Another possible pathway that has been suggested is the passage of infected leucocytes through the BBB (Desforges et al. 2014). This mechanism of neurotropism has been demonstrated in the case of the human immunodeficiency virus (HIV) and SARS-CoV-1(Kim et al. 2003; Spiegel et al. 2006; Nicholls et al. 2006; Trojanowicz et al. 2017). In SARS-CoV-2 infection, T cells facilitate viral infection but not replication (Wang et al. 2020a). Due to the widespread systemic effects of COVID-19, BBB permeability is increased, and hence CNS entry is gained through the passage of infected immune cells (Sankowski et al. 2015). These studies aiming to improve an understanding of SARS-CoV-2 neurotropism provide promising avenues for future research.

Coronavirus and Neurological Disorders

Multiple Sclerosis

The human coronavirus (HCV) has been used in several experimental models for the identification of the environmental component that triggers changes in the autoimmune system in multiple sclerosis (MS) cases (Sun 1995; Houtman et al. 1995; Wege 1995; Arbour 1999). An important role in MS pathophysiology is played by the toll-like receptors (TLRs) that are involved in the recognition of pathogens and host defense. Some researchers have postulated that these receptors recognize the viral particles and contribute to the modification of the immune response of patients developing MS. This interaction also suggests a probable link between viral infections (including CoV) and the development of demyelinating disease (Duffy and O’Reilly 2016). A large panel comprising samples of human brain autopsy was subjected to an observational study. This was done for targeted detection of HCV RNA. In addition, reverse transcription polymerase chain reaction (PCR) for OC43 and 229E CoV strains was performed on the samples collected from 39 patients affected by MS and 51 patients suffering from several varying neurological conditions or normal controls. A significantly higher prevalence of OC43 was reported in the results for individuals with MS as compared to the controls [35.9% (14 of 39) vs 13.7% (7 of 51)] (Arbour 2000). Another observational study showed that 4 out of 21 specimens from a white matter plaque, normal-appearing white matter, gray matter, and cervical cord tissue of MS patients tested for HCV-229E nucleic acid consistently gave positive results, while none of the 11 control brain specimens did so. A similar study reported the detection of murine-like CoV in 12 of 22 MS brains. Another study also reported that murine-like CoV was detected in 12 out of 22 MS brain specimens (Murray 1992). In addition to the isolation of HCV from the brains of patients suffering from MS, this association is supported by the observation of particles that appeared to be similar to the CoV in perivascular cuffing of an MS plaque intrathecal synthesis of antibodies to HCV-OC43 and HCV-229E in a significant number of patients suffering from MS (Stewart et al. 1992). Persistence of the infection in a leukocyte cell line and direct inoculation of the endothelial cells that act as a BBB enables CoV to infect dendritic cells and macrophages. It also enables CoV to effect changes in the whole innate immune system (Gerna 2007). In a separate study, experimental modeling was performed on susceptible strains of mice that were inoculated with the CoV JHMV strain. The results showed the development of an acute encephalomyelitis followed by a chronic demyelinating disease (Libbey et al. 2014). Multiple models of murine CoV have been used to induce demyelinating diseases in rodents (Houtman et al. 1995), either through a consistent infection of astrocytes and oligodendrocytes or through autoimmune simulation against the myelin basic protein. The reason for this is the contribution to the postulated molecular mimicry depicted by it (Boucher 2007). However, irrespective of all these findings that have expressed some association between the alpha and beta CoV along with the demyelinating disease, no connection can be demonstrated between MS and SARS-CoV-2, though a subsequent association cannot be ruled out.

Acute Disseminated Encephalomyelitis

Several experimental studies that inoculated CoV in mice showed a loss of myelin in the mouse spinal cords during the acute phase of the acute disseminated encephalomyelitis (ADEM) (Wu and Perlman 1999), and subsequent destruction of myelin after around 2–3 weeks of infection (Savarin 2008; Fehr and Perlman 2015). There was another case where a 15-year-old patient exhibited signs of initial upper respiratory symptoms along with subsequent ADEM. In this case, the nasopharyngeal specimens and the CSF showed positive results for HCV-OC43 (Yeh 2004). Another report pertaining to the case of a 71-year-old patient who tested positive for MERS-CoV noted that on the 24th day of the disease, new lesions were discovered in the patient’s bilateral pons, corpus callosum, periventricular deep white matter, upper cervical cord, left cerebellum, and midbrain (Algahtani et al. 2016). Further clinical research is needed to support the relationship between CoV and ADEM, even though the evidence indicates the persistence of the CoV RNA in the nervous system after the infection’s acute phase has occurred and has already caused neuronal loss.

Viral Encephalitis

Encephalitis leads to inflammatory lesions in the brain parenchyma that are caused by pathogens and include nerve tissue lesions and neuronal damage. This condition is characterized by its acute onset, and common symptoms include vomiting, high fever, convulsions, headache, and consciousness disorders (Ellul and Solomon 2018). Early diagnosis of the condition is critical for patient survival. A treatment team from the Beijing Ditan Hospital reported that during the ongoing pneumonia epidemic, the presence of SARS-CoV-2 was confirmed in the CSF of COVID-19 patients through genome sequencing. This presented clinical verification of the presence of viral encephalitis (Xiang et al. 2020) and offered clear indications for encephalitis caused by CoV.

Infectious Toxic Encephalitis

Infectious toxic encephalitis, also known as acute toxic encephalopathy, is related to a specific type of reversible brain dysfunction syndrome, which is a result of several factors including metabolism disorders, toxemia, and hypoxia experienced during the process of acute infection (Mizuguchi et al. 2007; Tauber et al. 2017; Young 2013). Cerebral edema is one of the basic pathological changes witnessed during this condition, although CSF analysis indicates no evidence of inflammation. The clinical symptoms of the condition are diverse and complex. Patients suffering from a mild course of the disease can develop mental disorders, headache, delirium, and dysphoria, whereas patients who are seriously affected can experience loss of consciousness, disorientation, paralysis, and coma (Dobbs 2011; Mizuguchi et al. 2007). Another significant cause of this condition is an acute viral infection, which has been exemplified by a respiratory infection caused by CoV. Severe viremia and hypoxia are often observed in patients suffering from COVID-19 (Guo et al. 2020), as they have the potential to lead to toxic encephalopathy. Additionally, almost 40% of patients with COVID-19 develop symptoms such as disturbed consciousness, headache, and other symptoms of brain dysfunction (Mao et al. 2020). Another autopsy study revealed that edema was detected in the brain tissues of COVID-19 patients (Xu et al. 2020b). Although detailed studies are urgently needed, these findings collectively indicate that infectious toxic encephalopathy can be caused by COVID-19.

Acute Encephalitis

In one study, HCV-OC43 testing was used to investigate the notion that an infectious respiratory pathogen could infiltrate the CNS, ultimately leading to swelling and neuroinflammation. The study reported that the infection caused neuronal degeneration, which eventually led to neuronal apoptosis. After the inoculation of HCV-OC43 in susceptible mice samples, the mice developed acute encephalitis, with viral RNA present for several months in surviving animals leading to neural degeneration (Jacomy et al. 2006). Full-length HCV-OC43 RNA was recovered from the brain of an 11-month-old boy who exhibited symptoms of viral encephalitis and severe combined immunodeficiency after cord blood transplantation. The patient was unable to survive and died 1.5 months after transplantation. Two months after the onset of symptoms, RNA sequencing of a brain biopsy sample was obtained, and it exhibited the presence of HCV-OC43. This diagnosis was further confirmed by brain immunohistochemical analysis and real-time PCR (Morfopoulou 2016). After a 3-day history of fever, cough, and altered psychological status, necrotizing hemorrhagic encephalitis was found in a middle-aged woman affected by COVID-19. Non-contrast computed tomography (CT) images of the head showcased symmetric hypoattenuation within the bilateral medial thalami. Magnetic resonance imaging (MRI) further demonstrated hemorrhagic lesions within the medial temporal lobes, bilateral thalami, and sub-insular regions (Poyiadji 2020). In yet another case, after experiencing fever, headache, and fatigue, a 24-year-old man presented with altered mental status and seizures, which further led to impaired consciousness. Laboratory and clinical evidence indicated viral meningoencephalitis, and detection of SARS-CoV-2 was determined in the RT-PCR analysis of the CSF. A brain MRI was conducted and showed alterations in the right wall of the lateral ventricle, the right mesial temporal lobe, and the hippocampus, indicating SARS-CoV-2 meningitis. Surprisingly, the results for SARS-CoV-2 were negative in the RT-PCR of the nasopharyngeal swab specimen, raising the possibility of COVID-19 independent mechanisms of neuropathogenesis (Moriguchi 2020). Conclusive evidence for establishing the relationship between COVID-19 and encephalitis is still needed, despite the postulated mechanisms of clinical reports and neuronal colonization.

Acute Cerebrovascular Disease

Substantial available evidence points specifically to respiratory-related infection as an independent risk factor for acute cerebrovascular disease (Elkind 2007; Warren-Gash et al. 2018). Data derived from an experimental mouse model indicate that ischemic brain injury can be aggravated by the influenza virus, which triggers a cytokine cascade and significantly enhances the risk of cerebral hemorrhage post-treatment with a tissue-type plasminogen activator (Muhammad et al. 2011). It has been widely reported that SARS-CoV-2 can cause cytokine storm syndromes, which might be one factor indicating that acute cerebrobasilar disease can be caused by CoV (Mehta et al. 2020; Chen et al. 2020d). A severe reduction in the platelet count and an increase in D-dimer levels are exhibited by critically ill patients severely affected by SARS-CoV-2. This can render patients vulnerable to different acute cerebrovascular events (Wang et al. 2020b). Hence, there is a significant likelihood that patients with a risk of developing cerebrovascular disease during CoV infections must be alert to the occurrence of acute cerebrovascular events.

Cerebrovascular Disease

One of the lesser-known complications of viral CNS infections is stroke. In Singapore, out of 206 SARS-CoV patients, five patients were reported to have large vessel stroke. Out of the four patients who were reported to be critically ill, three eventually died. In two patients, significant hypotension occurred just prior to the onset of stroke, along with disseminated intravascular coagulation and cardiac dysfunction (Umapathi 2004). An observational report pertaining to patients who were critically infected with SARS-CoV found an increased incidence of venous thromboembolism among patients (Lew 2003). A case series in Wuhan reported the occurrence of 14 strokes among a total of 214 patients affected by COVID-19. The data revealed that patients who exhibited cardiovascular risk factors and severe systemic presentation were extremely likely to be affected by acute cerebrovascular disease (Mao et al. 2020). In another retrospective study, stroke occurred in elderly patients who were affected with COVID-19 and exhibited multiple cardiovascular risk factors. In all cases, the mechanism of vascular damage was documented as large vessel disease (Avula 2020). More recently, five cases of stroke were reported in the context of COVID-19. Various vascular risk factors including hypertension, diabetes, and dyslipidemia were present in three of the younger patients. In all of these cases, evidence of large vessel occlusion was documented, and these vessels were treated with endovascular therapy. However, this association between stroke and COVID-19 is likely due to the similar risk factors shared by the two conditions. Adequate evidence is available that indicates the seriousness of COVID-19 infection in humans pertaining to the presence of different cardiovascular comorbidities such as diabetes and hypertension and large vessel disease in the elderly (Guo 2020). A recent meta-analysis comprising eight studies from China covering 46,248 infected patients indicated that the highly prevalent comorbidities were diabetes (8%) and hypertension (17%), followed by heart conditions (cardiovascular diseases) (5%) (Yang 2020; Zhou 2020). In several cases where patients exhibited no substantial vascular risk factors, the highly significant cerebrovascular disease mechanism was the hypercoagulability induced by SARS-CoV-2 (Avula 2020; Panigada 2020). When it comes to COVID-19 infection, there is an increased risk of stroke in those patients who have exhibited an earlier history of different vascular risk factors (Guo 2020; Yang 2020; Zhou 2020). Additionally, there is a chance that such patients will face severe complications such as hypotension, arrhythmogenic cardiomyopathy, shock heart failure, and disseminated intravascular coagulation. This could most certainly lead to large vessel occlusion, embolic mechanisms of stroke, and hypoperfusion (Wang et al. 2020c; Chen 2020d; Avula 2020; Zhou 2020; Oxley et al. 2020). In a detailed observational study that comprised 138 patients affected by COVID-19, 7.2% of the patients showed indications of the presence of acute cardiac injury, 8.7% of infected patients exhibited shock, and 16.7% showed symptoms of arrhythmia (Wang et al. 2020d). Another observational study conducted on 191 patients in China showed that 20% of the patients had septic shock complication, 17% had acute cardiac injury, 23% had heart failure, and 19% had coagulopathy (Zhou 2020). All these risk factors potentially predispose patients to stroke (Powers 2019). Further research is required to clarify the presence of specific viral factors that directly cause arteritis, hypercoagulability, and endothelial dysfunction that might eventually lead to brain bleeding or ischemic stroke (Powers 2019).

Guillain-Barré Syndrome (GBS) and Peripheral Nerve Disorders

Guillain-Barré syndrome (GBS) is an uncommon neurological condition in which the body's immune system mistakenly attacks part of the PNS (the network of nerves located outside of the brain and spinal cord). GBS is also known as acute inflammatory demyelinating polyneuropathy (AIDP), which can develop after a respiratory/gastrointestinal infection (Nguyen and Taylor 2020). It is supposed that a molecular mimicry mechanism of viruses, in which infecting viruses likely share epitopes similar to components of peripheral nerves (which activate autoreactive B or T cells), is accountable for its occurrence. The immune system produces antibodies, which are responsible to fight the virus cross-react and bind to components of the PNS, causing neuronal dysfunction. After SARS-CoV-1 infections both AIDP and acute motor axonal neuropathy (AMAN) variants have been reported (Tsai et al. 2005). Cases of Bickerstaff brainstem encephalitis, AMAN, and AIDP have been reported in the setting of MERS-CoV (Kim et al. 2017). However, reports of GBS in patients with COVID-19 are emerging. In Italy, a case series reported five cases of GBS after COVID-19 infection (Toscano et al. 2020). In four cases, patients developed lower-extremity weakness and presented paresthesias. Patients developed symptoms a mean of 5–10 days after onset of viral symptoms. Electromyography studies showed that three patients had AMAN and two had AIDP. Additional case reports describe a patient from Italy with Miller-Fisher-variant GBS and a patient in Iran with AMAN (Gutierrez-Ortiz et al. 2020; Sedaghat and Karimi 2020). A clinical case of acute transverse myelitis was also reported from Wuhan, but related CSF and MRI findings were not available. The patient presented flaccid lower-extremity paralysis with loss of pinprick sensation and paresthesias below the T10 level, and was effectively treated with intravenous immunoglobulin and steroids (Zhao et al. 2020a, b, c).

Other Related Neurological Complications

Loss of taste (dysgeusia/ageusia) and perturbation of smell (hyposmia/anosmia) have been reported as one of the striking manifestations of symptoms in patients with COVID-19. However, there are several uncertainties involved, including the specificity of the symptoms and the frequency of the symptoms as a probable diagnostic clue for COVID-19 in comparison to other symptomatically similar ailments like influenza, and the implications for the understanding of the pathogenesis of the virus. Impairment of smell was noticeable in 5% of the 214 hospitalized patients, and a loss of taste was reported in 6% of the patients in the Wuhan COVID-19 series (Mao et al. 2020). As a result of incomplete evaluations in the hospitalized patients, it is probable that the frequency of these symptoms were underrepresented. A subsequent study was conducted on 31 patients, in which a loss of smell was reported in 81% of the COVID-19 patients (29% hyposmia, 46% anosmia, and 6% dysosmia), while impaired sense of taste was reported in 94% (23% hypogeusia, 45% ageusia, and 26% dysgeusia) (Beltran-Corbellini et al. 2020). As reported, the disorders pertaining to loss of smell and taste had an average duration of 7.1 ± 3.1 days. A European study conducted at multiple centers on 417 cases with mild-to-moderate COVID-19 disease revealed a similarly higher frequency (86%) of patients suffering from olfactory dysfunction, with 20% and 80% of the patients manifesting hyposmia and anosmia, respectively (Lechien et al. 2020). Within 8 days of the onset of symptoms, 70% of the patients had recovered.

There have been suggestions that gustatory or olfactory dysfunction can indicate neuroinvasion and offers a route to the cardiorespiratory centers in the medulla from the oropharynx or the nasopharynx. These suggestions are based on studies conducted on transgenic mice infected by SARS-CoV and expressing the human SARS virus receptor (ACE2). At present there is no evidence to support host entry through this pathway in humans (Netlandet al. 2008). The direct infection from the virus and the subsequent killing of the gustatory and olfactory neurons in many patients may seem highly unlikely due to the transient nature of the dysfunction (Galougahi et al. 2020). Of the Wuhan COVID-19 series, 11% of patients reportedly exhibited evidence of skeletal muscle injury, which is defined as skeletal muscle pain and creatine kinase (CK) > 200 U/L (Mao et al. 2020). Patients with severe disease (19%) exhibited injury more commonly than patients with non-severe disease (5%) (p < 0.001). However, unfortunately, other than the presence of the associated muscle pain, there are virtually no clinical details available. Two subsequent reports point to the presence of rhabdomyolysis as a hallmark or a late complication of COVID-19 (Suwanwongse and Shabarek 2020; Jin and Tong 2020). One of the patients exhibited weakness along with limb pain, with peak myoglobin > 12,000 µg/L and CK of approximately 12,000 U/L, while another patient reported peak CK of 13,581 U/L. Although the mechanism of the injury is still to be determined, no muscle biopsy was performed on either of the patients.

Immunological Aspects of Pathogenic SARS-CoV-2 and Implications for Treatment of Neurological Complications

Amongst the extremely confusing hallmarks of SARS-CoV-2 infection is that almost 80% of patients, especially young adults or children, either exhibit minor symptoms or are asymptomatic. Only 20% of COVID-19 patients experience notable symptoms of infection, with extremely varying degrees of harshness. However, a definitive understanding of SARS-CoV-2 immunopathogenesis from the knowledge that we have gathered on SARS-CoV is elusive. The first line of defense for the suppression of various neurotropic viruses at the point of entry or distribution is the successful production of type I interferon (IFN) response. Suppression of the downstream signaling of type I IFN response by SARS-CoV occurs with the assistance of various mechanisms, which are closely related to the severity of the disease (Channappanavar and Perlman 2017). As there is overall genomic similarity of over 80% between SARS-CoV and SARS-CoV-2, and they both use the same receptor, it is reasonable to expect that the innate immune mechanisms involved in pathogenesis are almost identical for the two viruses. Multiple strategies have been developed by SARS-CoV to optimize its replication ability and to evade the innate immune response (Nelemans and Kikkert 2019), and it seems that the same strategies are used by SARS-CoV-2. To exercise any control over the replication of the virus without actually causing any immunopathogenic injury, it is important to accurately calibrate the response of the immune system in front of SARS-CoV-2. A significant role is played by the hyperinflammatory response in acute respiratory distress syndrome (ARDS), where in a subset comprising children, it can lead to the development of a multi-system inflammatory disorder such as Kawasaki disease (Bryce et al. 2020).

Elevated lung cytokine/chemokine levels along with the associated vascular leakage and lethal pneumonia results from rapid SARS-CoV replication and delay in IFN-I signaling, which is responsible for inflammatory monocyte-macrophage accumulation. This is in turn related to suboptimal T-cell response to SARS-CoV and reduction in the number of T cells (Channappanavar et al. 2016). Similar patterns were found in a study on 522 patients who were infected with COVID-19, which revealed that the total number of T cells, as well as CD4⁺ and CD8⁺ cells, were dramatically reduced, especially in patients who required ICU care. T-cell numbers were negatively correlated with serum IL-10, IL-6, and TNF-α concentrations. Conversely, patients who were in the period of disease resolution exhibited lowered serum IL-10, IL-6, and TNF-α levels as well as restored T-cell counts (Diao et al. 2020). These data were substantiated by other groups who witnessed a reduction in type I IFN response in patients who were severely affected (Qin et al. 2020; Trouillet-Assant et al. 2020). Moreover, there have been suggestions that delayed and reduced production of IFN-γ (“too little too late”) in the lungs and reduction in both CD4 and CD8 T cells can occur in combination, which may lead to viral injury by a reduction in the control of the replication of the virus and enhancement of pro-inflammatory cytokine upregulation, including IL-10, IL-6, and TNF-α (“cytokine storm”), and it may be the immune dysregulation as much or more than the direct viral infection that results in pulmonary epithelial cell injury. Similar mechanisms could be operative in the CNS (Pedersen and Ho 2020). Moreover, the probable mechanisms for the dysregulation of the immune system and whether they play any role in the neuropathogenesis of COVID-19 are unknown. Although there is still obscurity regarding the sources of cytokines that are found in the serum, it is possible that they can be produced by lung macrophages. As observed in the transgenic mouse model of SARS-CoV, IL-6 can also come from neurons that are infected (Netland et al. 2008). In turn, lymphocytopenia can be caused by higher levels of circulating cytokines. TNF-α, which is a pro-inflammatory cytokine that interacts with the receptor TNFR1, can cause T-cell apoptosis and is reported to have increased expression in aged T cells (Aggarwal et al. 1999; Gupta et al. 2005). IL-6 contributes to host defense in response to infections, exhibiting both pro- and anti-inflammatory properties. However, a key pathological role has been demonstrated through the continual synthesis of IL-6 in chronic infection and inflammation (Gabay 2006; Jones and Jenkins 2018). IL-10, which is an inhibitory cytokine and prevents the proliferation of T cells, can also lead to the exhaustion of T cells. Moreover, levels of the programmed cell death receptor 1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) exhaustion markers are observed in the T cells of patients who have been affected by COVID-19 (Diao et al. 2020). Conversely, the cellular immune response to SARS-CoV-2 is weakened by the reduced number of CD8⁺ and CD4⁺ T lymphocytes in very extreme cases, thereby creating the scope for further replication of the virus. The use of corticosteroids can significantly compound this problem. Of note, in a study conducted on convalescent patients with SARS-CoV, responses of CD8⁺ T cells were extremely regular and of greater magnitude in comparison to CD4⁺ T cells (Li et al. 2008). Finally, histological features that indicate secondary hemophagocytic lymphohistiocytosis (sHLH) were suggested through an autopsy series of COVID-19 patients. This condition is also known as macrophage activation syndrome, which is characterized by an imbalance in adaptive and innate immune responses, with aberrant activation of macrophages and a blunted adaptive immune response (Bryce et al. 2020). This dysregulated immune response may play a role in the pathogenesis of COVID-19 encephalopathy. An increase in the levels of circulating pro-inflammatory cytokines can lead to alteration and confusion of consciousness. However, the elimination of virus-infected cells in the brain may not be possible due to the weakened T-cell response, which may further lead to neurological dysfunction. There is an urgent need of carefully conducted studies on T-cell response to SARS-CoV-2 and the CSF cytokine profile, along with postmortem studies, including the muscle tissues and CNS, to better understand the neuropathogenesis of COVID-19. These studies will help to gain a better understanding of whether the therapeutic strategies which are intended to completely stop pro-inflammatory cytokines (including the IL-6 inhibitors sarilumab and tocilizumab) can exert any significant positive effect on the encephalopathy, or whether corticosteroids are contraindicated where the adaptive cellular immune response to the viruses has been dampened. As efforts are being made to identify medications that can counter the deleterious inflammatory stage that is triggered by SARS-CoV-2, the outcomes of COVID-19 in patients exhibiting neurological diseases such as myasthenia gravis or MS who have been treated with immunomodulatory therapies can offer valuable lessons. While our understanding of the biological complexity of SARS-CoV-2 is still only in the nascent stage, it is certainly evident that a significant threat is posed by COVID-19 to the entire nervous system via the multifactorial pathogenic mechanisms and worldwide prevalence (Fig.5). As we are striving for a vaccine or a cure to counter the virus, an important role will be played by neurologists in diagnosing, investigating, and treating several of the neurological manifestations of COVID-19 (Table 1) (McArthur 2020).

Fig. 5.

Putative mechanisms underlying SARS-CoV-2 neuropathogenesis: SARS-CoV-2 neuropathogenic effects are likely multifactorial, including, involvement of the peripheral nervous system (PNS) and muscle, direct neuroinvasion of the central nervous system (CNS), manifestations of systemic disease, as well as through a post-infectious, immune-mediated mechanism. MOF: multi-organ failure. Phi (φ) denotes direct evidence of viral invasion (RT-PCR + , biopsy); star (★) denotes CNS inflammation (CSF pleocytosis and proteinoracchia) with no evidence of direct viral infection of CNS

Table 1.

SARS-CoV-2 infection and neurological conditions

S. no.	Neurological ailment	Pathogenesis	Clinical manifestations	Diagnostic testing in support of neurological ailment
1	Muscle injury	Myopathy or myositis?	Myalgia	Elevated creatine phosphokinase level
2	Acute disseminated encephalomyelitis	Post-infectious	Acute neurological symptoms and headache	MRI: Hyperintense FLAIR lesions with variable enhancement
3	Guillain-Barré syndrome (GBS)	Post-infectious	Flaccid muscle weakness	EMG/NCS: Abnormal CSF SARS-CoV-2 RT-PCR: NEG CSF: Increased protein, nl WBC
4	Encephalitis	Neuroinflammation	CNS dysfunction and impaired mental state	CSF SARS-CoV-2 RT-PCR: NEG CSF: Pleocytosis & elev. Pro EEG: Abnormal (slow, + focal) MRI: Nonspecific (? WM changes)
5	Encephalopathy	Endothelialitis, multiple organ failure, systemic inflammation, and hypoxemia	Impaired mental state	CSF SARS-CoV-2 RT-PCR: NEG CSF: nl cells and Pro EEG: Abnormal (slow) MRI: Nonspecific
6	Viral encephalitis	Brain parenchymal neuroinvasion	CNS dysfunction and impaired mental state	Brain Tissue: POS (Ag or RNA) CSF SARS-CoV-2 RT-PCR: POS CSF: Pleocytosis and elev. Pro MRI: New abnormality EEG: Abnormal (slow, + focal)
7	Ageusia/anosmia	? Peripheral vs. central neuroinvasion	Olfactory/ taste loss or impairment	Test reports showed abnormalities in smell or taste
8	Stroke	Coagulopathy	Focal motor or sensory loss	MRI: Ischemia or bleed, abnormal coagulation factors increased inflammatory markers
9	Viral meningitis	Subarachnoid invasion	Nuchal rigidity and headache	CSF SARS-CoV-2 RT PCR: POS CSF: Pleocytosis & elev. Pro MRI: Meningeal enhancement

Mechanisms Linking COVID-19 and Neurological Manifestations

The involvement of the human nervous system has been supported by several lines of evidence in MERS, SARS, and SARS-CoV-2 (COVID-19). It is still difficult to determine how the overall pathophysiology is related to the varied neurological features, that is, whether they result indirectly or directly from viral infections, or arise from further mechanisms such as sepsis, hypoxia, or MOF. One of the potential available mechanisms is through the immune-related pathway. It appears that COVID-19 possesses a pivotal immune component, as various studies have reported findings such as increased C-reactive protein (CRP) levels and lymphopenia in patients affected by the disease (Huang et al. 2019; Chen et al. 2020c; Mehta et al. 2020). One uncommon but fatal complication in COVID-19 that has recently gained significant attention, especially in those who exhibit severe disease, is cytokine storm syndrome, which includes secondary hemophagocytic lymphohistiocytosis (sHLH) (Mehta et al. 2020). Therefore, patients with severe COVID-19 are constantly monitored for increased levels of ferritin, which is indicative of hyperinflammation. It is worth noting that one of the studies reported lower platelet counts and lower lymphocyte levels in those COVID-19 patients who presented CNS symptoms as compared to patients who did not present with CNS involvement (Mao et al. 2020; Li et al. 2020a, b). An increase in D-dimer levels, which is a marker of endogenous fibrinolysis and a hypercoagulable state, has also been reported in patients with severe disease and can possibly explain why the development of acute cerebrovascular disease is extremely common in patients exhibiting symptoms (Mao et al. 2020; Li et al. 2020a, b). There have been suggestions that the risk of acute cerebrovascular disease can be reduced through the early targeting of anti-inflammatory pathways (Li et al. 2020a, b).

Concluding Remarks

The neurological connection in SARS-CoV-2 and other CoV infections is an ever-expanding area of interest for neuroscientists. There are several reports that advocate the neurological manifestations of SARS-CoV-2 and COVID-19 pathogenesis. Most importantly, numerous mechanisms, including post-infectious immune-mediated processes, direct virus infection of the CNS, and virus-induced hyperinflammation, are commonly involved in SARS-CoV-2 neuropathology. Furthermore, CNS and PNS diseases such as Guillain-Barré syndrome and its variants, dysfunction of taste and smell, muscle injury, hemorrhagic and ischemic stroke, encephalitis, and meningitis are reported to be associated with SARS-CoV-2 infections. Needless to say, what we have learned is just the tip of the iceberg, and much remains to be understood in this domain for proper therapeutic intervention. Finally, improving our knowledge of SARS-CoV-2 neurobiology could enhance our understanding of neurological impairments with probable viral associations such as MS and viral encephalitis.

Author contributions

SKJ, DKC, GG, and KD collected the articles and initiated the draft of the review. HD, SKS, SDS, SB, NK, MJ, RJ, SM, RK, DK, VKG, JR, KKK, and SKS contributed to revision of the review. NKJ and SO edited the review and performed proofreading and final editing. All authors have read and approved the final manuscript.

Funding

There are no relevant funding sources to report.

Compliance with ethical standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Consent for publication: All co-authors have given their consent for publication.